Article
Efficacy of Ozurdex in DME in the real world clinical setting-DeSmet Interview
Professor Marc De Smet talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Redirect to video article
Related Videos
NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
Part 3: Biggest innovations in ophthalmology in 50 years
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
Part 2: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
Anat Loewenstein comments on the recent FDA approval of revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2 treatment
Related Content
